Table 1. Baseline Demographics and Disease Characteristics.
| Characteristics | Hematopoietic Stem Cell Transplantation (n = 55) | Disease-Modifying Therapy (n = 55) |
|---|---|---|
| Sex, No. (%) | ||
| Men | 21 (38) | 16 (34) |
| Women | 34 (62) | 39 (66) |
| Age, y | ||
| Mean (SD) | 35.6 (8.4) | 35.6 (8.2) |
| Median (range) | 34 (18-54) | 36 (19-52) |
| Duration of disease, mo | ||
| Mean (SD) | 63.1 (44.8) | 84.8 (61.2) |
| Median (range) | 56 (9-168) | 65 (8-255) |
| Prior immune modulation/suppression history, No. | ||
| Corticosteroids | 53 | 54 |
| Glatiramer acetate | 30 | 28 |
| Interferon beta-1a (Rebif) | 17 | 27 |
| Interferon beta-1a (Avonex) | 20 | 23 |
| Dimethyl fumarate | 12 | 12 |
| Interferon beta-1b | 15 | 11 |
| Natalizumab | 7 | 11 |
| Intravenous immunoglobulin | 3 | 3 |
| Fingolimod | 6 | 3 |
| Teriflunomide | 1 | 1 |
| Plasmapheresis | 0 | 1 |
| Azathioprine | 1 | 1 |
| Methotrexate | 1 | 0 |
| No. of different immune modulation/suppression treatments before hematopoietic stem cell transplantation | ||
| Mean (SD) | 3.2 (1.1) | 3.2 (1.2) |
| Median (range) | 3 (1-7) | 3 (1-7) |
| Baseline disability on Expanded Disability Status Scalea | ||
| Mean (SD) | 3.4 (1.2) | 3.3 (1.0) |
| Median (range)b | 3.0 (1.5-6.5) | 3.0 (1-6) |
| No. of gadolinium-enhancing lesions on baseline MRI | ||
| Mean (SD) | 4.5 (8.2) | 4.9 (8.4) |
| Median (range) | 2 (0-50) | 2 (0-41) |
| MRI T2-weighted lesion volume, cm3 | ||
| Mean (SD) | 16.4 (19.4) | 12.5 (13.6) |
| Median (range) | 8.2 (0.2-95) | 8.6 (0.1-58) |
Abbreviation: MRI, magnetic resonance imaging.
a
Score range, 0-10 in 0.5-point increments; higher scores indicate higher neurologic disability.10 An EDSS score of 3 indicates fully ambulatory but with moderate disability in 1 functional system or mild disability in 3 or 4 functional systems.
b
The EDSS scores at the time of enrollment were 2.0 to 6.0 in all patients.